Skip to main content
Erschienen in: Clinical & Experimental Metastasis 2/2022

13.01.2022 | Research Paper

Comparative associations of baseline frailty status and age with postoperative mortality and duration of hospital stay following metastatic brain tumor resection

verfasst von: Alis J. Dicpinigaitis, Simon Hanft, Jared B. Cooper, Chirag D. Gandhi, Syed Faraz Kazim, Meic H. Schmidt, Fawaz Al-Mufti, Christian A. Bowers

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Metastatic brain tumors are the most common intracranial neoplasms diagnosed in the United States. Although baseline frailty status has been validated as a robust predictor of morbidity and mortality across various surgical disciplines, evidence within cranial neurosurgical oncology is limited. Adult metastatic brain tumor patients treated with resection were identified in the National Inpatient Sample during the period of 2015–2018. Frailty was quantified using the 11-point modified frailty index (mFI-11) and its association with clinical endpoints was evaluated through complex samples multivariable logistic regression and receiver operating characteristic (ROC) curve analyses. Among 13,650 metastatic brain tumor patients identified (mean age 62.8 years), 26.8% (n = 3665) were robust (mFI = 0), 31.4% (n = 4660) were pre-frail (mFI = 1), 23.2% (n = 3165) were frail (mFI = 2), and 15.8% (n = 2160) were severely frail (mFI ≥ 3). On univariable assessment, these cohorts stratified by increasing frailty were significantly associated with postoperative complications (13.6%, 15.9%, 23.9%, 26.4%; p < 0.001), mortality (1.2%, 1.4%, 2.7%, 3.2%; p = 0.028), and extended length of stay (eLOS) (15.7%, 22.5%, 28.9%, 37.7%; p < 0.001). Following multivariable logistic regression analysis, frailty (by mFI-11) was independently associated with postoperative mortality (aOR 1.34, 95% CI 1.08, 1.65) and eLOS (aOR 1.26, 95% CI 1.17, 1.37), while increasing age was not associated with these endpoints. ROC curve analysis demonstrated superior discrimination of frailty (by mFI-11) in comparison with age for both mortality (AUC 0.61 vs. 0.58) and eLOS (AUC 0.61 vs. 0.53). Further statistical assessment through propensity score adjustment and decision tree analysis confirmed and extended the findings of the primary analytical models. Frailty may be a more robust predictor of postoperative outcomes in comparison with age following metastatic brain tumor resection.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ostrom QT, Wright CH, Barnholtz-Sloan JS (2018) Brain metastases: epidemiology. Handb Clin Neurol 149:27–42CrossRef Ostrom QT, Wright CH, Barnholtz-Sloan JS (2018) Brain metastases: epidemiology. Handb Clin Neurol 149:27–42CrossRef
2.
Zurück zum Zitat Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22(1):1–6CrossRef Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22(1):1–6CrossRef
3.
Zurück zum Zitat D’Andrea G, Palombi L, Minniti G, Pesce A, Marchetti P (2017) Brain metastases: surgical treatment and overall survival. World Neurosurg 97:169–177CrossRef D’Andrea G, Palombi L, Minniti G, Pesce A, Marchetti P (2017) Brain metastases: surgical treatment and overall survival. World Neurosurg 97:169–177CrossRef
4.
Zurück zum Zitat Sastry RA, Pertsch NJ, Tang O, Shao B, Toms SA, Weil RJ (2020) Frailty and outcomes after craniotomy for brain tumor. J Clin Neurosci 81:95–100CrossRef Sastry RA, Pertsch NJ, Tang O, Shao B, Toms SA, Weil RJ (2020) Frailty and outcomes after craniotomy for brain tumor. J Clin Neurosci 81:95–100CrossRef
5.
Zurück zum Zitat Bonney PA, Chartrain AG, Briggs RG et al (2021) Frailty is associated with in-hospital morbidity and nonroutine disposition in brain tumor patients undergoing craniotomy. World Neurosurg 146:e1045–e1053CrossRef Bonney PA, Chartrain AG, Briggs RG et al (2021) Frailty is associated with in-hospital morbidity and nonroutine disposition in brain tumor patients undergoing craniotomy. World Neurosurg 146:e1045–e1053CrossRef
6.
Zurück zum Zitat Khalafallah AM, Huq S, Jimenez AE, Brem H, Mukherjee D (2020) The 5-factor modified frailty index: an effective predictor of mortality in brain tumor patients. J Neurosurg 135:1–9CrossRef Khalafallah AM, Huq S, Jimenez AE, Brem H, Mukherjee D (2020) The 5-factor modified frailty index: an effective predictor of mortality in brain tumor patients. J Neurosurg 135:1–9CrossRef
7.
Zurück zum Zitat Pazniokas J, Gandhi C, Theriault B et al (2021) The immense heterogeneity of frailty in neurosurgery: a systematic literature review. Neurosurg Rev 44(1):189–201CrossRef Pazniokas J, Gandhi C, Theriault B et al (2021) The immense heterogeneity of frailty in neurosurgery: a systematic literature review. Neurosurg Rev 44(1):189–201CrossRef
8.
Zurück zum Zitat Dicpinigaitis AJ, Kalakoti P, Schmidt M et al (2021) Associations of baseline frailty status and age with outcomes in patients undergoing vestibular schwannoma resection. JAMA Otolaryngol Head Neck Surg 174:608CrossRef Dicpinigaitis AJ, Kalakoti P, Schmidt M et al (2021) Associations of baseline frailty status and age with outcomes in patients undergoing vestibular schwannoma resection. JAMA Otolaryngol Head Neck Surg 174:608CrossRef
9.
Zurück zum Zitat Casazza GC, McIntyre MK, Gurgel RK et al (2020) Increasing frailty, not increasing age, results in increased length of stay following vestibular schwannoma surgery. Otol Neurotol 41(10):e1243–e1249CrossRef Casazza GC, McIntyre MK, Gurgel RK et al (2020) Increasing frailty, not increasing age, results in increased length of stay following vestibular schwannoma surgery. Otol Neurotol 41(10):e1243–e1249CrossRef
10.
Zurück zum Zitat Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I (2013) Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res 183(1):104–110CrossRef Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I (2013) Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res 183(1):104–110CrossRef
11.
Zurück zum Zitat Belsley DA, Kuh E, Welsch RE (2005) Regression diagnostics: identifying influential data and sources of collinearity. Wiley, New Jersy Belsley DA, Kuh E, Welsch RE (2005) Regression diagnostics: identifying influential data and sources of collinearity. Wiley, New Jersy
12.
Zurück zum Zitat Richardson AM, McCarthy DJ, Sandhu J et al (2019) Predictors of successful discharge of patients on postoperative day 1 after craniotomy for brain tumor. World Neurosurg 126:e869–e877CrossRef Richardson AM, McCarthy DJ, Sandhu J et al (2019) Predictors of successful discharge of patients on postoperative day 1 after craniotomy for brain tumor. World Neurosurg 126:e869–e877CrossRef
13.
Zurück zum Zitat Huq S, Khalafallah AM, Jimenez AE et al (2020) Predicting postoperative outcomes in brain tumor patients with a 5-factor modified frailty index. Neurosurgery 88(1):147–154CrossRef Huq S, Khalafallah AM, Jimenez AE et al (2020) Predicting postoperative outcomes in brain tumor patients with a 5-factor modified frailty index. Neurosurgery 88(1):147–154CrossRef
14.
Zurück zum Zitat Shahrestani S, Lehrich BM, Tafreshi AR et al (2020) The role of frailty in geriatric cranial neurosurgery for primary central nervous system neoplasms. Neurosurg Focus 49(4):E15CrossRef Shahrestani S, Lehrich BM, Tafreshi AR et al (2020) The role of frailty in geriatric cranial neurosurgery for primary central nervous system neoplasms. Neurosurg Focus 49(4):E15CrossRef
15.
Zurück zum Zitat Khalafallah AM, Jimenez AE, Patel P, Huq S, Azmeh O, Mukherjee D (2020) A novel online calculator predicting short-term postoperative outcomes in patients with metastatic brain tumors. J Neurooncol 149(3):429–436CrossRef Khalafallah AM, Jimenez AE, Patel P, Huq S, Azmeh O, Mukherjee D (2020) A novel online calculator predicting short-term postoperative outcomes in patients with metastatic brain tumors. J Neurooncol 149(3):429–436CrossRef
16.
Zurück zum Zitat Sanchez-Lorente D, Navarro-Ripoll R, Guzman R et al (2018) Prehabilitation in thoracic surgery. J Thorac Dis 10(Suppl 22):S2593-s2600CrossRef Sanchez-Lorente D, Navarro-Ripoll R, Guzman R et al (2018) Prehabilitation in thoracic surgery. J Thorac Dis 10(Suppl 22):S2593-s2600CrossRef
17.
Zurück zum Zitat Kow AW (2019) Prehabilitation and its role in geriatric surgery. Ann Acad Med Singap 48(11):386–392PubMed Kow AW (2019) Prehabilitation and its role in geriatric surgery. Ann Acad Med Singap 48(11):386–392PubMed
18.
Zurück zum Zitat Hijazi Y, Gondal U, Aziz O (2017) A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 39:156–162CrossRef Hijazi Y, Gondal U, Aziz O (2017) A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 39:156–162CrossRef
19.
Zurück zum Zitat McIntyre MK, Gandhi C, Long A et al (2019) Age predicts outcomes better than frailty following aneurysmal subarachnoid hemorrhage: a retrospective cohort analysis. Clin Neurol Neurosurg 187:105558CrossRef McIntyre MK, Gandhi C, Long A et al (2019) Age predicts outcomes better than frailty following aneurysmal subarachnoid hemorrhage: a retrospective cohort analysis. Clin Neurol Neurosurg 187:105558CrossRef
20.
Zurück zum Zitat Terret C, Albrand G, Moncenix G, Droz JP (2011) Karnofsky performance scale (KPS) or physical performance test (PPT)? that is the question. Crit Rev Oncol Hematol 77(2):142–147CrossRef Terret C, Albrand G, Moncenix G, Droz JP (2011) Karnofsky performance scale (KPS) or physical performance test (PPT)? that is the question. Crit Rev Oncol Hematol 77(2):142–147CrossRef
21.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRef Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRef
22.
Zurück zum Zitat Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661CrossRef Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661CrossRef
23.
Zurück zum Zitat Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47(4):1001–1006CrossRef Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47(4):1001–1006CrossRef
24.
Zurück zum Zitat Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751CrossRef Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751CrossRef
25.
Zurück zum Zitat Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425CrossRef Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425CrossRef
26.
Zurück zum Zitat Turrentine FE, Wang H, Simpson VB, Jones RS (2006) Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 203(6):865–877CrossRef Turrentine FE, Wang H, Simpson VB, Jones RS (2006) Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 203(6):865–877CrossRef
Metadaten
Titel
Comparative associations of baseline frailty status and age with postoperative mortality and duration of hospital stay following metastatic brain tumor resection
verfasst von
Alis J. Dicpinigaitis
Simon Hanft
Jared B. Cooper
Chirag D. Gandhi
Syed Faraz Kazim
Meic H. Schmidt
Fawaz Al-Mufti
Christian A. Bowers
Publikationsdatum
13.01.2022
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 2/2022
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-021-10138-3

Weitere Artikel der Ausgabe 2/2022

Clinical & Experimental Metastasis 2/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.